Users online: 1248    [ij] [ij] [ij] 
Email id

Research Journal of Pharmacy and Technology
Year : 2018, Volume : 11, Issue : 12
First page : ( 5293) Last page : ( 5296)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2018.00964.2

Cardioprotective Activity of Telmisartan, Metformin and its Combination against Doxorubicin Induced Myocardial Infarction in Rat Model

Aruna P.1,*, Gayathiri N. M.2

1Department of Pharmacology, PSG College of Pharmacy, Coimbatore

2Assistant Professor, Department of Pharmacology, Swamy Vivekanandha College of Pharmacy, Tiruchengode-637 205

*Corresponding Author E-mail: arunapharm92@gmail.com

Online published on 18 May, 2019.



The present study was designed to investigate the cardioprotective activity of telmisartan, metformin and its combination against doxorubicin induced myocardial infarction in rat by biochemical analysis.


The therapeutic usefulness of doxorubicin (DXR), an anthracycline antibiotic, is limited by its cardiotoxicity. The study was conducted in albino wister rats (n=24) by using doxorubicin as negative control. the test drug, telmisartan and metformin was given alone and in combination for 15 days orally, on 14th & 15th day doxorubicin(15mg/kg) was injected intraperitoneally after the drug admistration except the normal control group.


The biochemical parameters, Troponin T shown to be negative for drug treated groups and positive for doxorubicin group (negative control). lactate dehydrogenase and CK-MB decreased for drug treated group then the negative control.


These results suggest that the telmisartan and metformin treatment provides a significant cardioprotecive protective effect against acute-doxorubicin induced myocardial infarction in rats.



Telmisartan, Metformin, doxorubicin, cardiotoxicity, cardioprotective effect.


║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
598,354,921 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.